Is Mirum Pharmaceuticals, Inc. (MIRM) Emerging as a Rare Disease Growth Story After New FOP Data?

We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is among the best healthcare stocks.

TheFly reported on June 15 that Citizens reiterated its positive stance on MIRM, increasing its price objective to $146 from $140. The firm pointed to the growing potential of Mirum’s recently acquired zilurgisertib program, citing updated findings that demonstrated encouraging clinical activity in fibrodysplasia ossificans progressiva (FOP). Although the Phase 2b study did not achieve its primary goal, the additional data strengthened the view that the therapy could still advance toward regulatory approval. Citizens also highlighted the asset’s commercial prospects and noted that its integration with Mirum’s existing operations could support a relatively rapid contribution to the company’s business.

Separately, on June 11, Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) announced that its Compensation Committee approved inducement awards on June 10, 2026, for eight newly hired employees under the company’s 2020 Inducement Plan. The grants included non-qualified stock options covering 10,100 shares of common stock and 13,350 restricted stock units (RSUs), issued in accordance with Nasdaq Listing Rule 5635(c)(4) as part of the employees’ hiring incentives. The stock options were granted at an exercise price of $94.00 per share, matching the company’s closing stock price on the grant date, and will vest over four years. The RSUs will vest over three years, with both awards remaining subject to continued employment and the terms of the applicable award agreements.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is a commercial-stage biopharmaceutical company developing therapies for rare diseases, with a focus on liver and metabolic disorders caused by bile acid dysfunction.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.